Results 221 to 230 of about 184,127 (310)

Nurse‐coordinated multidisciplinary comprehensive heart failure management programme: A propensity‐matched trial

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Despite therapeutic advancements, the prognosis of heart failure (HF) remains poor, with high rates of mortality and readmission, particularly following a HF exacerbation. This study aimed to evaluate the effects of a nurse‐coordinated multidisciplinary comprehensive HF management programme on HF patients.
Cecilia Miu‐Ching Chan   +13 more
wiley   +1 more source

Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA‐MI

open access: yesESC Heart Failure, EarlyView.
We investigated cardiometabolic outcomes in patients treated with dapagliflozin 10 mg once daily or placebo after acute myocardial infarction according to LVEF at randomisation in the registry‐based, randomised DAPA‐MI trial. Regardless of baseline LVEF, dapagliflozin resulted in significant cardiometabolic benefits versus placebo, suggesting that ...
David Erlinge   +19 more
wiley   +1 more source

Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor–Induced Upper Airway Angioedema

open access: hybrid, 2017
Richard Sinert   +9 more
openalex   +1 more source

Finerenone in diabetic chronic kidney disease—Real‐world insights including patients with HFpEF or HFmrEF

open access: yesESC Heart Failure, EarlyView.
Abstract Purpose Finerenone, a highly selective non‐steroidal mineralocorticoid receptor antagonist, was approved for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (diabetic kidney disease, DKD). Finerenone reduced the composite endpoint of heart failure events and cardiovascular death in patients with heart ...
Kristian Hellenkamp   +9 more
wiley   +1 more source

Novel mutation associated with non‐compaction ventricular myocardium: A case report

open access: yes
ESC Heart Failure, EarlyView.
Yan Li   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy